Dosing & Administration

AMVUTTRA® is dosed 4 times per year via subcutaneous injection1

AMVUTTRA® (vutrisiran) product image

AMVUTTRA® is dosed 4 times per year via subcutaneous injection1

  • The recommended dose of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months by a healthcare professional.1
    (See section 2.2 of full Prescribing Information for complete Administration Instructions.)
  • AMVUTTRA is provided as a fixed dose (25 mg/0.5 mL) prefilled syringe—no dose adjustments are recommended.1
  • If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose.1
  • Home administration may be an option for some patients. The decision for a patient to receive treatment at home should be made after an evaluation and recommendation by the treating physician and may not be covered by all insurance plans.

Premedication and laboratory monitoring are not required for AMVUTTRA.

Picture of dosing and administration brochure

Learn more about dosing and administration.

Administering AMVUTTRA
Administration of AMVUTTRA® (vutrisiran) video

Watch this instructional video for healthcare professionals

Walk through the steps for AMVUTTRA administration.

Treatment center icon
Find a treatment center
Locate the treatment center closest to your patient.
Circle check icon
Stay informed
Receive relevant content and updates.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).


AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.


  1. AMVUTTRA Prescribing Information. Cambridge MA: Alnylam Pharmaceuticals, Inc.